Timing note: Clorox is scheduled to report today, Monday, August 3, 2026, not tomorrow: results and prepared remarks are due at 4:15 p.m. ET, followed by a 5:00 p.m. ET analyst Q&A webcast.
Clorox’s fiscal Q4 report is less about a clean year-over-year earnings comparison and more about whether the company has exited FY2026 with:
The headline year-over-year Q4 comparison will be unusually distorted. FY2025 Q4 benefited from retailer inventory built ahead of Clorox’s ERP implementation—adding roughly 13–14 points of sales growth and $0.85–$0.95 of EPS. That creates a demanding reported comparison but a relatively favorable underlying setup as that distortion laps.
After fiscal Q3, Clorox cut its FY2026 outlook, largely because of GOJO transaction costs, delayed cost savings, ERP-related operating costs earlier in the year, and incremental energy/supply-chain inflation.
| Metric | FY2026 outlook as of Q3 |
|---|---|
| Net sales | Down ~6% |
| Organic sales | Down ~9% |
| Gross margin | Down 250–300 bps |
| Adjusted EPS | $5.45–$5.65 |
| GAAP diluted EPS | $4.78–$4.98 |
| GOJO impact on sales | Just under +3 points |
| GOJO impact on adjusted EPS | $(0.02)–$(0.04) |
Management also indicated at its June investor conference that Q4 organic sales should be about flat excluding the noise from the ERP comparison and GOJO. That statement is arguably the core operational benchmark for the release.
Using reported Q1–Q3 adjusted EPS of $0.85, $1.39, and $1.64, respectively, the FY guide implies fiscal Q4 adjusted EPS of roughly:
The comparable FY2025 Q4 adjusted EPS was $2.87, but that quarter included the large ERP-related pull-forward benefit. Therefore, the more useful question is whether Clorox can deliver the implied Q4 result while showing an underlying sales and margin trajectory that supports FY2027 improvement.
Based on FY2025 revenue of $7.10 billion and FY2026 guidance for sales to decline about 6%, the outlook implies fiscal Q4 revenue of approximately $1.9 billion, down roughly 4% year over year. This too is heavily influenced by the unusually elevated prior-year base.
Clorox described Q3 as mixed: organic sales declined 1%, and company sales were flat. Health & Wellness was flat, Household grew 3%, Lifestyle fell 9%, and International organic sales grew 2%.
The important qualitative message was sequential improvement in market-share trends—but not enough improvement. Investors should focus on whether the company can demonstrate that its operational disruption is now behind it and that investments are translating into measurable share progress.
Areas to watch:
A quarter that achieves the earnings guide but shows no share progress—particularly in litter—would likely be viewed poorly.
Q3 gross margin fell 140 bps year over year to 43.2%, hurt by higher manufacturing and logistics expenses and unfavorable mix. For Q4, management flagged an incremental $20–$25 million supply-chain inflation headwind tied to energy costs, equal to just under 150 bps of gross-margin pressure.
Management indicated reported Q4 gross margin could be only 41–42%, although it estimated that excluding roughly 150 bps of GOJO-related transaction and inventory-step-up costs, the underlying figure would be around 43%.
That distinction is important:
Investors should demand clarity on the timing of pricing, productivity, procurement actions, and mix recovery needed to offset energy, logistics, and commodity pressure in FY2027.
Clorox completed the roughly $2.25 billion acquisition of GOJO, maker of Purell, on April 1. Q4 will be the first full quarter in which the business is part of results.
The strategic appeal is clear: Purell expands Clorox’s health-and-hygiene portfolio, deepens its professional/B2B reach, and provides a recurring revenue element through GOJO’s installed dispenser base. Management has characterized GOJO as an approximately $800 million business growing at a mid-single-digit rate, with potential for mid- to high-single-digit growth over time.
However, GOJO changes the P&L mix:
The acquisition is expected to be neutral to EBITDA and EPS in the first year, then accretive in year two. The Q4 call should establish whether integration, retention, customer receptivity, and synergy identification are proceeding as planned.
The FY2026 result is depressed by the reversal of FY2025’s ERP-related shipment pull-forward. Management has quantified this as a roughly $0.90 EPS headwind in FY2026. That headwind should reverse in FY2027.
At the June conference, management framed three exceptional FY2027 items:
The market will likely look through the arithmetic and focus on the quality of the underlying framework:
A credible FY2027 framework could matter more than a modest Q4 EPS beat or miss.
Chair and CEO Linda Rendle has initiated a transition process for health reasons and will remain in her roles until a successor is appointed. Clorox subsequently appointed Chris Hyder as COO and Nina Barton as Chief Growth & Strategy Officer.
The earnings call should provide an opportunity to assess whether the company’s operating priorities, capital-allocation discipline, and GOJO integration plans remain intact through the transition. Investors will also listen for any indication that the COO appointment is part of longer-term succession planning.
The GOJO acquisition was debt-financed, and management expects to finish FY2026 at about 3.6x debt/EBITDA, versus its stated long-term target of 2.0x–2.5x. It intends to return to roughly 2.5x within two years.
Implications:
CLX closed at $95.55 on July 31, essentially flat versus its $96.44 close immediately before the April 30 Q3 report, while the S&P 500 rose about 4% over that period. The stock fell sharply following the Q3 release and updated outlook, suggesting investors remain skeptical about margin pressure, consumer softness, market-share recovery, and the execution burden from GOJO and the CEO transition.
That creates room for a positive reaction if Clorox can pair an in-line Q4 with credible evidence of:
The central issue is not whether Clorox clears a mechanically depressed FY2026 Q4 comparison. It is whether the company can demonstrate that FY2026 was the trough year created by ERP timing, integration costs, and temporary inflation—not the beginning of a structurally weaker earnings profile.